ST吉药(300108) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥87,654,699.88, representing an increase of 11.28% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥92,705,703.31, a decrease of 75.19% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥77,100,146.33, down 62.84% from the previous year[3]. - Net loss for Q3 2024 amounted to CNY 293,959,707.99, compared to a net loss of CNY 201,336,570.29 in Q3 2023, indicating a deterioration in financial performance[16]. - The total comprehensive income attributable to the parent company for Q3 2024 was -293,959,707.99 CNY, compared to -201,336,570.29 CNY in the same period last year, reflecting a significant decline[17]. - Basic and diluted earnings per share for Q3 2024 were both -0.3472 CNY, compared to -0.2164 CNY in Q3 2023, indicating worsening profitability[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,782,605,523.00, a decrease of 6.86% from the end of the previous year[3]. - The company's total assets decreased to CNY 1,782,605,523.00 from CNY 1,913,801,546.81, a decline of approximately 6.8%[14]. - Total liabilities increased to CNY 2,883,698,512.58, up from CNY 2,720,934,828.40, representing a rise of 6.0%[14]. - The company's non-current liabilities totaled CNY 836,473,243.45, compared to CNY 823,437,518.54 in the previous year, showing a slight increase[14]. - The total equity attributable to shareholders of the parent company was negative CNY 511,908,815.25, worsening from negative CNY 280,671,891.27 in the previous year, indicating a decline in shareholder value[14]. Cash Flow - The net cash flow from operating activities was -¥5,562,046.78, a decrease of 296.15% year-on-year[8]. - Cash inflow from operating activities for Q3 2024 was 206,939,799.73 CNY, down from 238,776,318.34 CNY in Q3 2023, representing a decrease of approximately 13.3%[18]. - Net cash flow from operating activities for Q3 2024 was -5,562,046.78 CNY, contrasting with a positive cash flow of 2,835,537.70 CNY in the previous year[18]. - Cash inflow from investment activities for Q3 2024 was 13,808,463.89 CNY, down from 17,990,241.68 CNY in Q3 2023, a decline of about 23.8%[19]. - Net cash flow from investment activities for Q3 2024 was -186,207.61 CNY, compared to -7,189,465.47 CNY in the same period last year, indicating improved cash flow performance despite remaining negative[19]. - Cash inflow from financing activities for Q3 2024 was 4,404,144.74 CNY, down from 6,339,609.38 CNY in Q3 2023, a decrease of approximately 30.6%[19]. - The net increase in cash and cash equivalents for Q3 2024 was -2,823,095.16 CNY, compared to -4,709,823.35 CNY in Q3 2023, showing a reduction in cash outflow[19]. - The ending balance of cash and cash equivalents for Q3 2024 was 19,977,185.15 CNY, compared to 18,607,210.48 CNY at the end of Q3 2023, indicating a year-over-year increase[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 19,476[10]. - The company has a total of 12,771,300 restricted shares at the end of the reporting period, with 3,316,050 shares newly added during the period[11]. - The company’s shareholder Huang Kefeng is identified as the spouse of controlling shareholder Lu Zhongkui, indicating potential related party transactions[10]. Inventory and Impairment - The inventory at the end of the period decreased by 50.15% to ¥58,048,573.84 due to impairment provisions[7]. - The company recognized an asset impairment loss of -¥43,913,014.14 primarily related to inventory[8]. - Inventory decreased significantly from CNY 116,440,299.16 to CNY 58,048,573.84, representing a decrease of about 50%[12]. Financing and Expenses - The company reported a significant increase in financing receivables, which rose by 73.63% to ¥24,118,682.99[7]. - The company reported a total of CNY 24,118,682.99 in accounts receivable financing, an increase from CNY 13,891,226.35 at the beginning of the period[12]. - Research and development expenses for Q3 2024 were CNY 5,307,154.95, a decrease from CNY 6,129,842.08 in the previous year, reflecting a reduction in investment in innovation[15]. - The company reported a significant increase in financial expenses, totaling CNY 130,150,632.24, compared to CNY 125,122,640.58 in the same quarter last year[15].